Automated Microinjection of Recombinant BCL-X into Mouse Zygotes Enhances Embryo Development by Liu, Xinyu et al.
Automated Microinjection of Recombinant BCL-X into
Mouse Zygotes Enhances Embryo Development
Xinyu Liu
1.¤, Roxanne Fernandes
2., Marina Gertsenstein
2, Alagammal Perumalsamy
2, Ingrid Lai
2,
Maggie Chi
3, Kelle H. Moley
3, Ellen Greenblatt
4, Igor Jurisica
5, Robert F. Casper
2,4, Yu Sun
1*, Andrea
Jurisicova
2,4*
1Department of Mechanical and Industrial Engineering and Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada,
2Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, 3Department of Obstetrics and Gynecology, Washington University in St. Louis, St.
Louis, Missouri, United States of America, 4Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada, 5Departments of Computer
Science and Medical Biophysics, Ontario Cancer Institute and the Campbell Family Institute for Cancer Research, University Health Network, University of Toronto, Toronto,
Ontario, Canada
Abstract
Progression of fertilized mammalian oocytes through cleavage, blastocyst formation and implantation depends on
successful implementation of the developmental program, which becomes established during oogenesis. The identification
of ooplasmic factors, which are responsible for successful embryo development, is thus crucial in designing possible
molecular therapies for infertility intervention. However, systematic evaluation of molecular targets has been hampered by
the lack of techniques for efficient delivery of molecules into embryos. We have developed an automated robotic
microinjection system for delivering cell impermeable compounds into preimplantation embryos with a high post-injection
survival rate. In this paper, we report the performance of the system on microinjection of mouse embryos. Furthermore,
using this system we provide the first evidence that recombinant BCL-XL (recBCL-XL) protein is effective in preventing early
embryo arrest imposed by suboptimal culture environment. We demonstrate that microinjection of recBCL-XL protein into
early-stage embryos repairs mitochondrial bioenergetics, prevents reactive oxygen species (ROS) accumulation, and
enhances preimplantation embryo development. This approach may lead to a possible treatment option for patients with
repeated in vitro fertilization (IVF) failure due to poor embryo quality.
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Introduction
According to the Centre for Disease Control, one in every eight
North American couples seeks medical treatment for infertility.
Embryo quality remains a strong determining factor for predicting
the outcome of assisted reproductive technology (ART) [1].
Molecular defects responsible for failed preimplantation develop-
ment are frequently attributed to poor oocyte quality of unknown
etiology. Mathematical modeling of death rates in human
preimplantation embryos has suggested that the factors predis-
posing an embryo to arrest are determined at or even before the
zygote stage [2,3]. The ability of the conceptus to pass through the
transition from maternal to zygotic control in vitro has been
proposed to be a function of the cytoplasmic components of the
oocyte with minimal impact of the newly formed zygotic genome
[4]. Thus, oocytes must possess cytoplasmic components which
accumulate during oogenesis and support development through
the blocking stage [5], and these components are lacking or non-
functional in those embryos that arrest.
Ooplasm transfer experiments demonstrated that an unidenti-
fied ooplasmic factor(s) can prevent embryo arrest [6]. This
pioneering work led to controversial clinical attempts to rescue
human embryos with poor developmental potential by transferring
‘healthy’ donor ooplasm into recipient oocytes prone to abnormal
development [7]. Such ooplasm transfers in humans were
performed for patients with increased maternal age, repeated
embryonic developmental failure or poor ovarian reserve, and
have resulted in the birth of at least thirty children worldwide [8].
Unfortunately, transfer of ooplasm results in offspring carrying
mitochondria from both the donor and recipient, thus creating
mitochondrial heteroplasmy [9]. While benefits of this mitochon-
drial enrichment are clearly evident during the early developmen-
tal stages, mitochondrial heteroplasmy can have late physiological
consequences [10]. Therefore, it is desirable to identify the
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21687molecular ‘‘culprits’’ responsible for suboptimal oocyte quality and
devise molecular strategies for both fundamental research and
treatment options.
Microinjection is a well established approach for introducing
molecules into mammalian oocytes/embryos. High speed, high
reproducibility, and high survival rate upon injection are critically
important for testing the efficacy of potential molecular therapeu-
tics. Due to the inherent difficulty of manipulating small-sized
(,100 mm), delicate mammalian embryos, conventional manual
microinjection requires a long learning curve and suffers from low
throughput.
The past decade has witnessed significant efforts to automate
microinjectionusing robotictechnologies[11,12,13,14,15,16,17,18],
and several robotic systems were demonstrated for assisting mouse
embryo injection [11,12,18]. However, these robotic systems
inherited the architecture directly from manual operation and only
automated a few steps, while several difficult procedures (e.g., cell
search, immobilization, and orientation) still must be conducted by a
human operator with extensive training. Taking a different system
architecture from manual operation and existing robotic systems, we
havedevelopeda novelroboticsystemthatleveragesmotioncontrol,
computer vision microscopy, and micro device technology to
achieve automated microinjection with high speed, reproducibility,
and post-injection survival rate. This system employs microfabri-
cated cell holding devices and vision-position-based control of
multiple micropositioning devices to achieve easy sample immobi-
lization, rapid cell orientation, and fast injection of mouse embryos.
Technical aspects of the system were described previously [19,20].
This paper reports the testing results of optimal system
performance (e.g., injection speed and survival rate), based on
the injection of a large number of mouse zygotes; and
demonstrates a novel strategy for preventing early embryo arrest
enabled by robotic microinjection of recombinant proteins into
mouse zygotes. We provide the first quantitative evaluation of the
efficacy of an anti-apoptotic recombinant protein BCL-XL
(recBCL-XL) on rescuing early mouse embryos cultured in a
suboptimal condition.
Results
Automated Microinjection of Mouse Zygotes
In contrast to conventional manual injection systems, our
robotic system (Figure 1A) uses a microfabricated glass cell holding
device (Figures 1C and S1A) to immobilize many mouse zygotes
into a regular pattern (Figure S1C, Text S1, and Video S1).
Switching from one cell to another for injection was greatly
simplified and automatically performed via precise position control
(Figures S2–S3, Text S1, and Video S2), dramatically enhancing
the injection speed. A vision-based cell orientation control
technique (Text S1) as well as an in-house developed motorized
Figure 1. Automated robotic microinjection of mouse zygotes. (A) The robotic system employs a glass micro device to immobilize a large
number of mouse zygotes into a regular pattern via fine vacuum and micrometer-sized through holes underneath cells. Based on precise position
control and microscopy vision feedback, a three-degrees-of-freedom (3-DOF) micromanipulator, a motorized X-Y stage, and an in-house developed
rotational stage are automatically controlled by a host computer to control an injection micropipette and position/orient the zygotes, respectively.
An inverted microscope mounted with a digital camera is used to provide visual feedback and therefore, guide motions of the micropipette and
zygotes to achieve automated microinjection. (B) A mouse zygote with the tip of a micropipette at the cytoplasmic center after material deposition. A
droplet of mineral oil, which is easy to observe under a non-fluorescent microscope, was injected for visualization to verify the success of material
deposition into the cytoplasmic center. (C) Schematic of the glass micro device for zygote immobilization. Vacuum is applied to each zygote for
immobilization via micrometer-sized through holes. (D) Mouse zygotes robotically injected with PBS buffer are developed into blastocysts. (E)
Calibration data of deposition volumes as a function of deposition time and pressure. Micropipettes with an opening of 1.2 mm were used, as shown
in the inlet. (F) Automated robotic microinjection induced significantly lower lysis rates than manual injection (n=400 for robotic protein and buffer
injection; n=229 for manual injection). Bars indicate mean 6 s.e.m. Kruskal Wallis test followed by Dunn’s post test was used for statistical analysis.
doi:10.1371/journal.pone.0021687.g001
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for fast and automated cell orientation. A motorized microma-
nipulator (i.e., injection microrobot) was automatically controlled
to inject mouse zygotes (Figure 1B and Video S2) in a high-speed
manner with high repeatability.
During system development, 306 mouse zygotes were injected
with PBS buffer by the robotic system. Through these trials, an
injection speed of 200 mm/s and a retraction speed of 500 mm/s
were experimentally determined to be optimal in terms of
minimizing injection-induced cell lysis. In order to ensure viability
of injected zygotes and investigate dose effects of the injected
materials, deposition volume was accurately controlled (Figure 1E),
achieved by fabricating injection micropipettes with a high
consistency and precisely regulating the pressure unit output (Text
S1). The resolution of material deposition volume was 1 femtoliter
(fL).
To quantify system performance, the robotic system injected an
additional 240 mouse zygotes with PBS buffer, demonstrating an
average injection speed of 12 zygotes/min (vs. ,2 zygotes/min in
manual injection by highly skilled technicians, data provided by
microinjection operators at the Toronto Center for Phenoge-
nomics). Based on visual inspection right after injection, the
robotic system achieved a low cell lysis rate (1.1%, Table 1).
Developmental competence of microinjected embryos assessed by
the rate of blastocyst formation (Table 1) in vitro after 96 hours in
culture was 8961.3% (mean 6 s.e.m.), indicating minimal
detrimental effect of robotic injection on embryo quality.
Due to the higher viscosity of the recombinant proteins (vs. PBS
buffer), we next determined the need for increased size of
microinjection pipettes. This modification increased the embryo
lysis rates (20.3%; Figure 1F); however, the robotic system still
provided significantly lower lysis rates than manual injection
(37.7%; Figure 1F). There was no significant difference between
the lysis rates of protein injection or buffer injection produced by
robotic and manual microinjection. Thus, the robotic system has
better performance in terms of cellular damage caused by
microinjection. Automation enables users to operate the system
without the long training needed for microinjection while
achieving high injection consistency.
Culture induced developmental arrest
To use the system to address interesting questions in
developmental biology, we focused on devising strategies for
overcoming early embryo arrest. Outbred colonies of mice often
exhibit compromised preimplantation embryo development in
suboptimal culture conditions [21]. We first determined that
human tubal fluid (HTF) medium, often used by in-vitro
fertilization (IVF) clinics in the past, delays mouse preimplantation
embryo development in vitro (Figures 2A and 2B). The HTF
culturing model well recapitulates developmental arrest and was
used to study the impact of ooplasmic transfer in the mouse model
[22]. We and others have previously reported that embryos of
suboptimal quality often exhibit altered expression levels of genes
known to regulate cell death [23,24]. In addition, females lacking
Bcl-x (officially called Bcl2L1) in their oocytes exhibit decreased
breeding performance that could not be attributed to a defect in
ovarian reserve [25]. In order to determine whether altered levels
of Bcl-2 family members accompany embryo arrest in the mouse,
we explored if BCL-X protein levels changed in 2-cell stage mouse
embryos due to culture in HTF medium.
Immunocytochemistry revealed ,25% reduction of BCL-X
protein expression in the embryos that were cultured for 24 hours
in HTF in comparison to potassium simplex optimization medium
(KSOM) (Figure 2C), most commonly used for in vitro culture of
murine embryos. These results suggest that the depletion of BCL-
X may contribute to poor embryo survival in the suboptimal
culture conditions and may be one of the cytoplasmic factors
responsible for improved embryo development observed during
ooplasmic rescue.
Enhancing embryo development by automated
microinjection of recBCL-XL (DTM)
Thus, we next attempted to transiently supplement BCL-X
levels by microinjecting recBCL-XL (DTM) [26] into zygotes and
to examine their in vitro developmental potential under an adverse
culture condition (HTF). Injection of recBCL-XL (DTM) protein
significantly improved preimplantation embryo development,
when compared to buffer-injected, HTF-cultured embryos
(p,0.001; Figure 3A). Rates of blastocyst formation, total cell
number (TCN) and cell death index (CDI), which all reflect
embryo quality, were restored by recBCL-XL (DTM) microinjec-
tion to levels comparable with embryos cultured in KSOM
medium (Figure 3A and Figure 2). As a negative control, we also
injected zygotes with BSA dissolved in microinjection buffer, and
this did not significantly improve developmental rates (47%;
n=66) or embryo quality (TCN: 6465.5%, CDI: 4.260.6;
n=13). These results show that microinjection of the recBCL-
XL (DTM) protein is capable of restoring developmental
competence and improving quality of embryos facing conditions
of stress. Furthermore, there was no significant difference in
studied outcomes if protein was delivered into the cytoplasm or
pronucleus (Figure S4). As robotic microinjection resulted in lower
lysis rates and a higher degree of consistency, all experiments
described below were performed with robotic recBCL-XL (DTM)
delivery into the cytoplasm.
Gametes and early mammalian embryos are susceptible to
damage caused by excessive reactive oxygen species (reviewed in
[27]). While reactive oxygen species (ROS) are key signaling
molecules mediating basic cellular functions such as proliferation,
differentiation and programmed death, excessive ROS production
Table 1. Statistics of non-lysis and blastocyst formation rates of mouse embryos with PBS injection using the robotic system.
Experiments 1 2 3 4567O v e r a l l
Number of injected embryos 18 18 27 27 50 50 50 240
Number of surviving embryos (day 1.5) 18 18 26 27 50 49 49 237
Number of blastocysts (day 4.5) 16 15 24 23 46 45 44 213
Non-lysis rate (%) 100 100 96.3 100 100 98 98 98.9±0.6 (mean±s.e.m.)
Blastocyst formation (%) 88.9 83.3 92.3 85.2 92 91.8 89.8 89±1.3 (mean±s.e.m.)
The injected embryos were cultured in KSOM medium.
doi:10.1371/journal.pone.0021687.t001
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permanent embryo arrest similar to that of cellular senescence
[28]. As BCL-X has been previously shown to have antioxidant
activities [29], we explored if BCL-X can increase developmental
competence via preventing ROS accumulation.
HTF medium triggered excessive production/accumulation of
ROS when compared to KSOM. Embryos microinjected with
recBCL-XL (DTM) protein and maintained in HTF medium had
significantly reduced ROS levels (Figure 3B). Supplementing HTF
medium with BCL-X derived BH4 domain TAT-synthetic peptide
was sufficient to maintain a physiological ROS profile (Figure S5).
However, developmental competence of embryos maintained in
medium supplemented with BH4 peptide was not restored. These
results indicate that the BH4 domain can alleviate excessive ROS,
but only full length BCL-X protein, albeit lacking the transmem-
brane region (BCL-XL(DTM)), is capable of effectively restoring
the developmental quality of embryos.
Previous work in bovine embryos identified the adaptor protein
p66SHC as a mediator of permanent embryo arrest. Develop-
mentally compromised bovine embryos have been reported to
exhibit higher p66SHC expression accompanied by elevated ROS
levels, and knockdown of p66Shc significantly reduced the
occurrence of permanent embryo arrest in the bovine model
[30,31]. Immunocytochemistry revealed that recBCL-XL (DTM)
microinjection decreased expression of both total and activated
(pSer-36) p66SHC (Figure 3C) protein. As the P-p66SHC isoform
has been shown to enter mitochondria and contribute to hydro-
gen peroxide release into the cytosol, decreased expression of
Figure 2. Impact of culture medium on developmental competence and BCL-X protein expression of mouse embryos. (A) HTF culture
medium induces 2-cell arrest in a subset of embryos and compromises preimplantation embryo development when compared to KSOM medium
(n=273 embryos/medium). Rates of blastocyst formation at day 4.5 (,96 hours in culture) as well as total cell number (TCN) are dramatically
reduced, while cell death index (CDI) is elevated (n=54 embryos for KSOM and n=36 embryos for HTF). Bars indicate mean 6 s.e.m. Mann Whitney
U-test was used for pairwise comparison. (B) Poor quality of embryos is also reflected by nuclear staining (DAPI), showing smaller blastocysts with
multiple apoptotic cells (arrows). (C) Expression of BCL-X protein is decreased in 2-cell embryos cultured for 24 hours in HTF medium. Significant
reduction in fluorescent intensity (RFU), generated after immunocytochemical analysis for BCL-X was detected in embryos cultured in HTF (n=10),
when compared to KSOM cultured embryos (n=9). Control embryos, exposed to no-specific IgG (n=6), exhibited only very small amount of
fluorescence, which was subtracted from the intensity generated by BCL-X antibody. Bars indicate mean 6 s.e.m. Student’s t-test was used for
calculating significance of difference between KSOM and HTF groups.
doi:10.1371/journal.pone.0021687.g002
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nied by lower ROS levels in recBCL-XL (DTM) microinjected
embryos.
Suboptimal culture conditions may result in both excessive
ROS production and the alteration of embryo metabolism. BCL-
X, in addition to its anti-apoptotic role, has also been implicated in
mitochondrial biogenesis [32] and the regulation of mitochondrial
metabolism [33]. Therefore, we next explored whether mitochon-
drial distribution, an indicator of embryo health [34,35], can be
altered by culture conditions. As anticipated, embryos cultured in
HTF medium exhibit altered sub-cellular distribution of mito-
chondria in comparison to KSOM (Figure S6). Furthermore, this
distribution was corrected by recBCL-XL (DTM) microinjection
(Figure 4A), indicating that this Bcl-2 family member is capable of
maintaining the correct cellular mitochondrial network in
developing embryos.
We have also explored mitochondrial copy number (mtDNA
content), mitochondrial activity (Mitotracker intensity) as well as
mitochondrial membrane potential (JC-1 ratio). However, none of
these parameters was affected by culture conditions or by BCL-X
microinjection (data not shown). Finally, we investigated if
recBCL-XL (DTM) microinjection can affect the metabolism of
preimplantation embryos. Early embryos are not capable of
glycolysis and rely on oxidative phosphorylation to sustain their
energy demands. With development, they progressively gain the
ability to utilize glucose [36]. Autofluorescent signals, reflecting
cellular content of reduced NAD(P)H and oxidized FAD were
significantly decreased in embryos upon microinjection of
recBCL-XL(DTM) protein with concomitant increase in the
citrate/ATP ratio (Figure 4B). Thus, BCL-X at the 2-cell stage
modulates mitochondrial output, with outcomes indicating more
efficient Krebs cycle metabolism and carbohydrate utilization.
Expression of BCL-X in human oocytes
While experiments described above dealt with in vitro induced
phenotype, they have clinical relevance to human IVF, where
Figure 3. Impact of recBCL-XL (DTM) microinjection on early embryo development. (A) Ability of mouse zygotes to progress through the
development and form blastocysts in suboptimal HTF medium were significantly increased upon microinjection of recBCL-XL (DTM) protein (n=424)
when compared to buffer injected embryos (n=414). In addition, total cell number (TCN) per embryo was significantly increased and cell death index
(CDI) was decreased (n=71 for buffer injection; n=110 for protein injection). Nuclear counterstaining (DAPI) images of blastocysts at day 4.5 reflect
differences in embryo quality. Mann-Whitney U-test was used for pairwise comparison. (B) Reactive oxygen species (ROS) accumulation, determined
by fluorescent measurement of DCHFDA probe fluoresce at 2-cell stage was determined 24 hours after microinjection of either buffer (n=15) or
recBCL-XL (DTM) protein (n=15) and relative fluorescence units (RFU) were used to express fluorescent signal. Injection of recBCL-XL (DTM)
significantly reduced the accumulation of ROS (student’s t-test). (C) Immunocytochemical analysis of total p66SHC or phosphorylated p66SHC on
Ser36 was decreased in embryos injected with recBcl-xL (DTM) (n=15/antibody), when compared to buffer injected embryos (n=15/antibody). In
addition, we noticed that Ser10 p66SHC (green) localized to the mitochondria (Mitotracker red), with preferential clustering in subcortical and peri-
nuclear regions (yellow overlap; arrows), but this was greatly reduced in recBCL-XL (DTM) microinjected embryos. Bars indicate mean 6 s.e.m.
doi:10.1371/journal.pone.0021687.g003
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addition, it is also possible that some oocytes may lack sufficient
storage of maternally derived Bcl-x gene products. In order to
determine if variability in the endowment of maternally accumu-
lated BCL-X transcripts could contribute to poor quality of human
embryos in patients undergoing IVF, we analyzed its expression in
human oocytes. As we have previously observed that Bcl-x
transcript expression peaks in germinal vesicle (GV) stage of
mouse oocytes, followed by dramatic decline in metaphase II stage
[23], we used only human GV and metaphase I (MI) arrested
oocytes. The GV and MI oocytes were analyzed separately.
Within the cohort of oocytes obtained from patients undergoing
infertility treatment, 6/72 GV and 14/65 MI oocytes failed to
express detectable levels of BCL-X transcripts. An additional sub-
group of oocytes (8 at GV stage) expressed reduced levels (less than
mean) of BCL-X transcripts (Figure 5A). These data indicate that
,20% of human growing oocytes obtained from infertile patients
either completely lack or possess diminished endowment of BCL-X
transcripts.
We next analyzed a possible link between BCL-X and genes
known to be significantly deregulated in human arrested or
fragmented embryos by considering known physical protein-
protein interactions from the I2D database. These targets included
genes ZAR1, YBX2, SYMPK, CPEB1, TARBP2, DICER1,
DGCR8, MYLC2, ECT2, DIAPH1, CFL1, NELF, BTF3,
IGFR2, YY1, TERT, DNMT3B, CTNNB1, HRK, BCL-XS,
BCL2L10, P27KIP1 [23,24,37,38,39]. The resulting protein
interaction network comprises 1,810 proteins and 20,562 interac-
tions. Thick edges represent direct interactions among 22 up- and
down-regulated genes/proteins. Thin, light grey edges link BCL-X
(BCL2L1) with the up- and down-regulated genes, via 25
additional protein partners (small circles). On the left side are
proteins that mostly link to down-regulated genes. EP300 is linked
to both up- and down-regulated targets, while CASP8 is most
linked to up-regulated genes (Figure 5B). This network highlights
how lack of BCL-X may be connected with targets known to be
differentially expressed in arrested embryos.
Discussion
Enabled by the microfabricated embryo holding devices and
vision-position based control of multiple motion control devices,
the robotic mouse embryo injection system is capable of fast
immobilization, switching, orientation, and injection of mouse
embryos. The automated system requires minimal human
involvement (i.e., a few computer mouse clicks), and is therefore,
independent of operator skills, enabling the acquisition of large-
scale molecule testing data with a high reproducibility. The robotic
system performed microinjection of mouse zygotes at a speed of 12
zygotes/min, six times the speed of manual injection (,2 zygotes/
min). High accuracy and consistency of the robotic system
produced lower cell lysis rates and higher blastocyst formation
rates than proficient microinjection technicians. Except the micro
devices for immobilizing embryos and the motorized rotational
stage for orienting cells, the automated system contains no other
custom developed components and presents no difference in
hardware compared to a conventional microinjection system,
which is an advantage promising its use in biology laboratories and
mouse core facilities. The robotic cell manipulation technology
presented here can also be adapted with further technological
modifications and applied to other cell micromanipulation tasks,
for instance, intracytoplasmic sperm injection (ICSI) and nuclear
transfer procedures.
Our experimental results suggest that embryo arrest caused by
suboptimal culture conditions is mostly driven by inefficient
metabolism, in part due to decreased Bcl-x expression triggered by
Figure 4. Impact of recBCL-XL (DTM) microinjection of embryo metabolism and mitochondrial distribution at 2-cell stage. (A)
Mitochondrial distribution (Mitotracker Red) at 2-cell stage was evaluated by computerized image analysis approach (extracted features; see Text S1)
and compared among cultured conditions. RecBCL-XL (DTM) protein maintained diffuse mitochondrial pattern (n=30 embryos), while buffer (n=30;
similar to HTF culture alone), caused preferential clustering of these organelles to subcortical and perinuclear regions (arrows) of 2-cell embryos
maintained in culture for 24 hours. (B) Microinjection of recBCL-XL (DTM) protein stabilized redox state of 2-cell stage embryos reduced (NAD(P)H and
oxidized FAD autofluorescence signal expressed in RFU; n=15 embryos per condition) and improved Krebs cycle outcome (Citrate/ATP ratio n=15
embryos per condition). Student’s t-test was used for statistical analysis. Bars indicate mean 6 s.e.m.
doi:10.1371/journal.pone.0021687.g004
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can be restored by the microinjection of recombinant BCL-X
protein, which repairs mitochondrial bioenergetics, prevents ROS
accumulation, and facilitates the development of preimplantation
mouse embryos. These effects start to become apparent at the 2-
cell stage, and the consequences are still evident in the blastocyst
stage (higher cell number and lower cell death rate; Figure 3A).
While Bcl-x deletion causes midgestational embryonic lethality
mostly due to defects in neuronal and hematopoietic lineages [40],
its haplo-insufficiency triggers ovarian follicle loss, which became
obvious with aging [41]. However, deletion of Bcl-x in follicles
(oocyte and granulosa cells) did not compromise ovarian reserve in
young age, but did result in decreased fertility of females [25].
We have previously shown that Bcl-x is maternally deposited
into the oocytes, but becomes upregulated, likely from embryonic
genome, at the late 1-cell stage [25]. In addition, some human as
well as murine fragmenting early embryos alter splicing of Bcl-x
gene, producing pro-apoptotic Bcl-xS isoform [24,25]. We have
recently shown that blastocysts do not require Bcl-xL for their
survival, as downregulation of this isoform at the morula stage did
Figure 5. Expression of BCL-X in human oocytes. (A) Distribution of human oocytes obtained form 43 patients based on their BCL-X expression
in either germinal vesicle stage (GV - left) or meiosis I stage (MI - right). Arrows point to groups of oocytes with insufficient endowment of BCL-X
transcript. (B) Visualization of protein interaction network that connects BCL-X (BC2L1) with other targets known to be deregulated in arrested human
embryos. Node shape, represented by triangles, indicates trends of expression. Shape of triangles pointing up corresponds to genes up-regulated
and triangles pointing down correspond to genes down-regulated in arrested human embryos; circles represent direct interacting partners that link
BCL-X (BCL2L1) to up- and down-regulated targets. Red highlight on nodes represents the set of cross-linked proteins. Node color is based on gene
ontology as per legend. To reduce network complexity, all other nodes and edges are made partially transparent.
doi:10.1371/journal.pone.0021687.g005
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with concomitant induction of Bcl-xS had detrimental develop-
mental consequences, as these blastocysts contain fewer cells and
suffer from increased oxidative stress [42]. Data from the current
study, however, point to a dependency on BCL-X during the
critical window of transition from maternal to embryonic control,
at the 2-cell stage.
The mechanism by which BCL-X promotes survival of 2-cell
embryos does not appear to involve suppression of apoptosis, but
rather points to the regulation of mitochondrial metabolism. These
findings are consistent with previously published results in yeast
and mammalian cell lines, which proposed that BCL-X can
regulate a metabolic switch from glycolysis to oxidative phosphor-
ylation [33], and can also maintain metabolite passage and activity
of VDAC under conditions of stress [43,44]. BCL-X and other
BCL-2 family members had also been shown to dynamically
remodel the mitochondrial network (e.g., fission and fusion;
reviewed in [45]). Thus, changes in mitochondrial distribution
without the effect on mitochondrial DNA copy number observed
in recBCL-XL microinjected embryos, are not surprising.
Intriguing is, however, the connection between phosphorylation
of p66SHC and BCL-X protein levels. It is presently unknown
how BCL-X influences the phosphorylation of p66SHC, besides
regulating ROS levels. Suppression of apoptosis by BCL-2 and
BCL-XL can be attributed to protection against ROS and/or a
shift of the cellular redox potential to a more reduced state [46].
Paradoxically, an elevated release of hydrogen peroxide was
observed from BCL-XL overexpressing mitochondria, which led
to an enhanced cellular antioxidant defense and superior
protection against death [47]. It is also possible that dual crosstalk
exists between BCL-X and p66SHC as previous work revealed
that ablation of p66SHC increased expression of BCL-XL [48].
However, our data point to an additional role of BCL-X besides
ROS safeguarding. While suboptimal culture clearly triggered
oxidative stress, it is unlikely that ROS is the sole reason behind
early embryo arrest, as BH4 peptide could alleviate the ROS
accumulation, but could not support further embryo development.
Likely, a combined role in mitochondrial metabolism with
physiological ROS maintenance facilitates the viability of early
embryos.
We have also attempted to explore if microinjection of recBCL-
XL protein could have a clinical relevance. Expression screen of
oocytes from infertile patients revealed variability in the BCL-X
endowment. Within the cohort of freshly collected immature
human oocytes, one-fifth either lacked or expressed lower amounts
of BCL-X transcripts. However, the level of BCL-X did not
correlate with clinical parameters such as patient infertility
diagnosis, maternal age, stimulation protocol as well as pregnancy
outcome (data not shown). We observed that oocytes from the
same patient would be variably affected, indicating that not all
oocytes are created equal and likely would not equally well support
preimplantation embryo development. We speculate that embryos
conceived from oocytes lacking BCL-X would be incapable of
progression through preimplantation development and would
arrest during in vitro culture. As we did not assess expression of
BCL-X in the transferred embryos, this may explain the lack of
BCL-X correlation with pregnancy outcome. Nonetheless, micro-
injection of recBCL-XL could have potential use during IVF
treatment, particularly for cases where patients experience
repeated IVF failure due to poor embryo quality.
Microinjection of recombinant mitochondrial proteins is
capable of improving the developmental competence of embryos
without genetic alterations in the offspring, a problematic factor of
ooplasmic transfer. In contrast to mitochondrial heteroplasmy that
results from ooplasmic transfer, the recombinant form of the BCL-
X protein has a terminal half-life. Therefore, its addition to the
embryos is aimed at providing transient support during the time
that embryos are most susceptible to demise without resulting in
permanent genetic modifications of the offspring. Further
screening of additional protein targets using the automated
microinjection technique could lead to the selection of the most
efficacious proteins for improving embryo survival.
Materials and Methods
Ethics Statement
All mouse experiments were performed in accordance with
Canadian Council on Animal Care (CCAC) guidelines for Use of
Animals in Research and Laboratory Animal Care under
protocols (permit or protocol #:AUP0015) approved by the
animal care committees at Mount Sinai Hospital (MSH), Toronto
and Toronto Centre for Phenogenomics (TCP). Single immature
human oocytes at germinal vesicle or metaphase I stage were
donated to research after obtaining patient consent approval in
writing, which was approved by the Research Ethics Board at
Mount Sinai Hospital, Toronto.
Mouse Embryo Collection and Culture
The collection and culture conditions of mouse embryos are
described in the Supporting Methods (Text S1).
Manual and Robotic Microinjection
The workstation for manual microinjection consisted of an
inverted microscope equipped with differential interference
contrast (DIC) optics (Leica Microsystems, Wetzlar, Germany).
Microinjection pipettes were backloaded and connected to a
microinjector (FemtoJet; Eppendorf, Hamburg Germany). Hold-
ing pipettes (100 mm O.D., 30 mm I.D.) were prepared on a
microforge (DeFonbrune) from 1.0 mm O.D.60.75 mm I.D.
borosilicate glass capillaries (FHC 27-30-0) and connected to a
manually controlled oil-based holding syringe system (Narishige,
Japan). Mouse zygotes with visible pronuclei were selected for
microinjection. All the zygotes were injected within the time
window of 1–3 hr post-collection.
Detailed description of the robotic microinjection system design
and operation is provided in the Supporting Methods (Text S1)
and Videos.
Measurement of Reactive Oxygen Species (ROS) Content
In the experiments, ROS content of the injected and un-
injected embryos was measured at the 2-cell stage. The level of
ROS content was quantified using the dichlorodihydrofluorescein
diacetate (DCHFDA, Molecular Probes, Invitrogen, Carlsbad,
CA, USA) method as previously described [49]. Live imaging and
quantitation were conducted on a deconvolution microscope
(Olympus IX70, Applied Precision Inc. Issaquah, WA, USA) using
an image analysis program (SoftwoRx, Applied Precision Inc.,
Issaquah, WA, USA).
Immunocytochemistry for pSHC and BCL-X
Embryos, fixed with 10% formalin, were incubated overnight
with appropriate primary antibody, rabbit anti-SHC (BD Trans-
duction laboratories), mouse anti-SHC/phospho S36 antibody
(Abcam) or rabbit anti mouse BCL-X (Santa Cruz, CA). After
washing, embryos were incubated with appropriate secondary
antibodies.Followinga15minutecounterstainwithDAPI,embryos
were mounted and imaged on a deconvolution microscope
(Olympus IX70; Applied Precision Inc., Issaquah, WA, USA),
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above.
Metabolic Assays and Mitochondrial Labeling
(Mitotracker)
Microanalytical metabolic assay for ATP and citrate levels were
performed as previously described [50]. Live embryos were stained
with Mitotracker Red (Molecular Probes, Invitrogen, Carlsbad,
CA, USA) at a final concentration of 200 mM. Embryos were then
imaged on a deconvolution microscope (Olympus IX70, Applied
Precision Inc., Issaquah, WA, USA) under the TRITC filter.
NAD(P)H and FAD autofluorescence of the embryos were also
imaged under DAPI and FITC filters, respectively as previously
described [51]. Quantitation of the mitochondrial DNA copy
number and mitochondrial membrane potential (JC-1, Molecular
probes, Invitrogen, Carlsbad, CA, USA) labeling was performed as
previously described [34] and distribution was evaluated as
outlined in Supporting Methods (Text S1).
Network Analysis and Visualization
Genes reported to be differentially expressed in human arrested
or fragmented embryos, were chosen based on previous publica-
tions [23,24,37,38,39]. These gene targets were mapped to
proteins and used to assess connectivity to BCL-X using the
known, physical protein-protein interactions. Network was gener-
ated by querying I2D database Version 1.95 [52,53]. Network
visualization was performed in NAViGaTOR 2.2 ([54,55]).
Statistical Analysis
Data were presented as mean 6 s.e.m. and analyzed using
either student’s t-test, Mann-Whitney U-test, or Kruskal Wallis test
followed by Dunn’s post test (SigmaStat 3.5, Systat Software Inc.),
as appropriate. For patient data analysis, Pearson correlation was
used for maternal age and Anova on Ranks for patient diagnosis,
hormonal stimulation and pregnancy outcome. All the statistical
analyses were performed using SigmaStat 3.5 (Systat Software
Inc.).
Supporting Information
Figure S1 Zygote immobilization using a glass-based
cell holding device. (A) A completed glass cell holding device.
(B) A zoomed-in picture of the through holes. (C)A5 65 array of
immobilized mouse zygotes using the cell holding device.
(TIF)
Figure S2 Overall flow of microrobotic mouse embryo
injection. (A) Contact between micropipette tip and cell holding
cavity is detected using a vision-based algorithm [15]. (B) The
micropipette tip is elevated to a home position H, and the first
embryo is brought into the field of view, recognized and centered.
If the polar body faces the penetration site, the embryo is properly
rotated through automatic orientation control. (C) Micropipette is
moved to a switch point, S.( D) The micropipette penetrates the
embryo and deposits materials to the target destination. (E) The
micropipette is retracted out of the embryo. (F) Micropipette is
moved to the home position. Simultaneously, the next embryo is
brought into the field of view. This injection process is repeated
until all the embryos in the batch are injected.
(TIF)
Figure S3 Mouse zygote orientation. (A) Side view and (B)
top view of the zygote and injection micropipette before
orientation. When the polar body appears in the space of
quadrant II, there are risks of either direct polar body penetration
or large stress induced polar body damage. The desired target
orientation is either 12 o’clock or 6 o’clock. (C) Top view of the
embryo after orientation. Polar body
(TIF)
Figure S4 Impact of injection modes of delivery (man-
ual vs. automated injection) on rates of blastocyst
formation and embryo quality. Both modes of delivery
significantly improved developmental potential of embryos
injected with recBCL-XL (DTM) protein (manual injection:
n=107 for buffer and n=122 for protein; automated injection:
n=307 for buffer and n=302 for protein). No significant
difference (p=0.359 for buffer injection; p=0.762 for protein
injection) was found between rates of blastocyst formation if
protein was delivered into either cytoplasm or pronucleus.
Microinjection of recBCL-XL (DTM) protein also significantly
enhanced the embryo quality (manual injection: n=39 for buffer
and n=65 for protein; automated injection: n=32 for buffer and
n=44 for protein). Bars indicate mean 6 s.e.m. Student’s t-test
was used for pairwise comparison.
(TIF)
Figure S5 Impact of culture medium on reactive oxygen
species (ROS) levels. Assessment of the relative amounts of
ROS measured by DCHFDA probe in 2-cell embryos cultured for
24 hours in KSOM (n=15), HTF (n=17), HTF with 15 ng/mlo f
BH4 peptide (n=15). Bars indicate mean 6 s.e.m. Kruskal Wallis
test followed by Dunn’s post test was used for statistical analysis.
(TIF)
Figure S6 Computationally quantitated mitochondrial
distributions at 2-cell stage in (A) un-injected and (B)
injected embryos. Using Euler number computation, mito-
chondrial distribution in un-injected embryos is significantly
altered by culture medium (n=19 for HTF; n=20 for KSOM),
which can be corrected by microinjection of recBCL-XL (DTM)
protein (n=22 for each condition). Bars indicate mean 6 s.e.m.
Mann-Whitney U-test was used for pairwise comparison.
(TIF)
Video S1 Vacuum-based cell immobilization using a
microfabricated glass device.
(MOV)
Video S2 Automated microinjection of mouse zygotes
using a robotic cell injection system.
(MOV)
Text S1 Supporting methods.
(DOC)
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